Increase of number of shares and votes in Hansa Medical AB (publ)

As previously announced, the general meeting of Hansa Medical AB (publ) resolved to adopt a warrant program 2015-2019 on June 2, 2015. As part of the completion of the program, 50,000 ordinary shares have been issued. The company’s registered share capital and number of outstanding shares and votes have thus increased during the month of July 2018.

As of today, the total number of registered and outstanding shares of Hansa Medical amounts to 38,463,386 whereof 38,133,125 are ordinary shares and 330,261 are Class C shares. As of today, the number of votes in Hansa Medical amounts to 38,166,151.1 and the registered share capital amounts to SEK 38,463,386.

This information is information that Hansa Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 8:00 am CEST on July 31, 2018.

For further information, please contact:
Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Medical AB (publ)
Mobile: 46707175477
E-mail: emanuel.bjorne@hansamedical.com

About Hansa Medical
Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead product, imlifidase (IdeS), is a proprietary antibody-degrading enzyme currently in late-stage clinical development for kidney transplant patients, with significant potential for further development in other solid organ transplants and in acute autoimmune indications. The company also has a strong pipeline of preclinical projects that may provide a second wave of potential drugs. Under the project name NiceR, novel immunoglobulin-cleaving enzymes are developed for repeat dosing with the objective of applying the Hansa Medical technology in relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden, and its shares are listed on Nasdaq Stockholm (ticker: HMED).

About Us

Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (HMED) is listed on Nasdaq First North in Stockholm with Remium Nordic AB as Certified Adviser.